Papers

Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study

^a Department of Social and Preventive Medicine and Outpatient Department of Internal Medicine, University of Berne, Berne, Switzerland, ^b Division of Infectious Diseases, University of Geneva, Geneva, ^c Division of Hospital Preventive Medicine and Infectious Diseases and Department of Social and Preventive Medicine, University of Lausanne, Lausanne, ^d Division of Infectious Diseases, University of Zurich, Zurich, ^e Division of Internal Medicine, Cantonal Hospital St Gall, St Gall, ^f Outpatient Department of Internal Medicine, University of Basle, Basle

The members of the Swiss HIV cohort study are listed at the end of the articleCorrespondence to: Dr M Egger Department of Social Medicine, University of Bristol, Canynge Hall, Bristol BS8 2PR m.egger@bristol.ac.uk

Objectives: To examine trends in disease progression and survival among patients enrolled in the Swiss HIV cohort study during 1988-96 and to assess the influence of new antiretroviral combination therapies.
Design: Prospective multicentre study, with follow up visits planned at six monthly intervals.
Setting: Seven HIV units at university centres and cantonal hospitals in Switzerland.
Patients: 3785 men (mean age 35.0 years) and 1391 women (30.3 years) infected with HIV. 2023 participants had a history of intravenous drug misuse; 1764 were men who had sex with men; 1261 were infected heterosexually; and 164 had other or unknown modes of transmission. 601 participants had had an AIDS defining illness.
Results: During more than 15 000 years of follow up, there were 1456 first AIDS defining diagnoses and 1903 deaths. Compared with those enrolled during 1988-90, the risk of progression to a first AIDS diagnosis was reduced by 18% (relative risk 0.82 (95% confidence interval 0.73 to 0.93)) among participants enrolled in 1991-2, by 23% (0.77 (0.65 to 0.91)) among those enrolled in 1993-4, and by 73% (0.27 (0.18 to 0.39)) among those enrolled in 1995-6. Mortality was reduced by 19% (0.81 (0.73 to 0.90)), 26% (0.74 (0.63 to 0.87)), and 62% (0.38 (0.25 to 0.97)) respectively. Compared with no antiretroviral treatment, the risk of an initial AIDS diagnosis after CD4 lymphocyte counts fell to <200 cellsx10⁶/l was reduced by 16% (0.84 (0.73 to 0.97)) with monotherapy, 24% (0.76 (0.63 to 0.91)) with dual therapy, and 42% (0.58 (0.37 to 0.92)) with triple therapy. Mortality was reduced by 23% (0.77 (0.68 to 0.88)), 31% (0.69 (0.60 to 0.80)), and 65% (0.35 (0.20 to 0.60)) respectively.
Conclusions: The introduction of antiretroviral combination therapies outside the selected patient groups included in clinical trials has led to comparable reductions in disease progression and mortality.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    Twitter    What's this?

Relevant Article

Antiretroviral combination therapy and HIV infection

Jim McMenamin, Gwen Allardice, David Goldberg, Tamiza Parpira, Gillian Raab, Rodolphe Thiébaut, Frantz Thiessard, Laurence Dequac Merchadou, Catherine Marimoutou, and François Dabis
BMJ 1998 317: 887. [Extract] [Full Text]

This article has been cited by other articles:

• The Antiretroviral Therapy Cohort Collaboration, (2009). Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 38: 1624-1633 [Abstract] [Full text]  
• The Swiss HIV Cohort Study, (2009). Cohort Profile: The Swiss HIV Cohort Study. Int J Epidemiol 0: dyp321v1-dyp321 [Full text]  
• Kaner, R. J., Santiago, F., Crystal, R. G. (2009). Up-regulation of alveolar macrophage matrix metalloproteinases in HIV1+ smokers with early emphysema. J. Leukoc. Biol. 86: 913-922 [Abstract] [Full text]  
• Borchardt, S M, Haufle, V, Whitaker, E E, Dworkin, M S (2009). Predictors of mortality among women with AIDS in Illinois, USA. Int J STD AIDS 20: 623-627 [Abstract] [Full text]  
• Torpey, K, Lartey, M, Amenyah, R, Addo, N A, Obeng-Baah, J, Rahman, Y, Suzuki, C, Mukadi, Y D, Colebunders, R (2009). Initiating antiretroviral treatment in a resource-constrained setting: does clinical staging effectively identify patients in need?. Int J STD AIDS 20: 395-398 [Abstract] [Full text]  
• Kitahata, M. M., Gange, S. J., Abraham, A. G., Merriman, B., Saag, M. S., Justice, A. C., Hogg, R. S., Deeks, S. G., Eron, J. J., Brooks, J. T., Rourke, S. B., Gill, M. J., Bosch, R. J., Martin, J. N., Klein, M. B., Jacobson, L. P., Rodriguez, B., Sterling, T. R., Kirk, G. D., Napravnik, S., Rachlis, A. R., Calzavara, L. M., Horberg, M. A., Silverberg, M. J., Gebo, K. A., Goedert, J. J., Benson, C. A., Collier, A. C., Van Rompaey, S. E., Crane, H. M., McKaig, R. G., Lau, B., Freeman, A. M., Moore, R. D., the NA-ACCORD Investigators, (2009). Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. NEJM 360: 1815-1826 [Abstract] [Full text]  
• Bopp, M., Spoerri, A., Zwahlen, M., Gutzwiller, F., Paccaud, F., Braun-Fahrlander, C., Rougemont, A., Egger, M. (2009). Cohort Profile: The Swiss National Cohort--a longitudinal study of 6.8 million people. Int J Epidemiol 38: 379-384 [Full text]  
• Joos, B., Fischer, M., Kuster, H., Pillai, S. K., Wong, J. K., Boni, J., Hirschel, B., Weber, R., Trkola, A., Gunthard, H. F., The Swiss HIV Cohort Study, (2008). HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc. Natl. Acad. Sci. USA 105: 16725-16730 [Abstract] [Full text]  
• Battegay, M., Fehr, J., Fluckiger, U., Elzi, L. (2008). Antiretroviral therapy of late presenters with advanced HIV disease. J Antimicrob Chemother 62: 41-44 [Abstract] [Full text]  
• May, M., Sterne, J. A C, Shipley, M., Brunner, E., d'Agostino, R., Whincup, P., Ben-Shlomo, Y., Carr, A., Ledergerber, B., Lundgren, J. D, Phillips, A. N, Massaro, J., Egger, M. (2007). A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. Int J Epidemiol 36: 1309-1318 [Abstract] [Full text]  
• Prasad, L., Spicher, V. M., Zwahlen, M., Rickenbach, M., Helbling, B., Negro, F., Swiss Hepatitis C Cohort Study Group, (2007). Cohort Profile: The Swiss Hepatitis C Cohort Study (SCCS). Int J Epidemiol 0: dym096v1-7 [Full text]  
• Kumar, A., Kilaru, K. R., Forde, S., Roach, T. C. (2006). Changing HIV Infection-Related Mortality Rate and Causes of Death Among Persons With HIV Infection Before and After the Introduction of Highly Active Antiretroviral Therapy: Analysis of All HIV-Related Deaths in Barbados, 1997-2005. J Int Assoc Physicians AIDS Care (Chic Ill) 5: 109-114 [Abstract]  
• The Data Collection on Adverse Events of Anti-HIV, (2006). Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus: The D:A:D Study.. Arch Intern Med 166: 1632-1641 [Abstract] [Full text]  
• Cain, L. E., Cole, S. R., Chmiel, J. S., Margolick, J. B., Rinaldo, C. R. Jr., Detels, R. (2006). Effect of Highly Active Antiretroviral Therapy on Multiple AIDS-defining Illnesses among Male HIV Seroconverters. Am J Epidemiol 163: 310-315 [Abstract] [Full text]  
• Chou, R., Huffman, L. H., Fu, R., Smits, A. K., Korthuis, P. T. (2005). Screening for HIV: A Review of the Evidence for the U.S. Preventive Services Task Force. ANN INTERN MED 143: 55-73 [Abstract] [Full text]  
• Egger, M., Boulle, A., Schechter, M., Miotti, P. (2005). Antiretroviral therapy in resource-poor settings: scaling up inequalities?. Int J Epidemiol 34: 509-512 [Full text]  
• Chu, J. H., Gange, S. J., Anastos, K., Minkoff, H., Cejtin, H., Bacon, M., Levine, A., Greenblatt, R. M. (2005). Hormonal Contraceptive Use and the Effectiveness of Highly Active Antiretroviral Therapy. Am J Epidemiol 161: 881-890 [Abstract] [Full text]  
• Orkin, C., Stebbing, J., Nelson, M., Bower, M., Johnson, M., Mandalia, S., Jones, R., Moyle, G., Fisher, M., Gazzard, B. (2005). A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study). J Antimicrob Chemother 55: 246-251 [Abstract] [Full text]  
• Giordano, T. P., Kramer, J. R., Souchek, J., Richardson, P., El-Serag, H. B. (2004). Cirrhosis and Hepatocellular Carcinoma in HIV-Infected Veterans With and Without the Hepatitis C Virus: A Cohort Study, 1992-2001. Arch Intern Med 164: 2349-2354 [Abstract] [Full text]  
• Yazdanpanah, Y., Sissoko, D., Egger, M., Mouton, Y., Zwahlen, M., Chene, G. (2004). Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials. BMJ 328: 249- [Abstract] [Full text]  
• Kaufmann, G. R., Perrin, L., Pantaleo, G., Opravil, M., Furrer, H., Telenti, A., Hirschel, B., Ledergerber, B., Vernazza, P., Bernasconi, E., Rickenbach, M., Egger, M., Battegay, M. (2003). CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years: The Swiss HIV Cohort Study. Arch Intern Med 163: 2187-2195 [Abstract] [Full text]  
• Amundsen, E. J., Fekjaer, H. (2003). Progression to AIDS slowed even more after the first two years with highly active antiretroviral therapy. Scand J Public Health 31: 312-318 [Abstract]  
• Fagard, C., Oxenius, A., Gunthard, H., Garcia, F., Le Braz, M., Mestre, G., Battegay, M., Furrer, H., Vernazza, P., Bernasconi, E., Telenti, A., Weber, R., Leduc, D., Yerly, S., Price, D., Dawson, S. J., Klimkait, T., Perneger, T. V., McLean, A., Clotet, B., Gatell, J. M., Perrin, L., Plana, M., Phillips, R., Hirschel, B. (2003). A Prospective Trial of Structured Treatment Interruptions in Human Immunodeficiency Virus Infection. Arch Intern Med 163: 1220-1226 [Abstract] [Full text]  
• Price, D. A., Scullard, G., Oxenius, A., Braganza, R., Beddows, S. A., Kazmi, S., Clarke, J. R., Johnson, G. E., Weber, J. N., Phillips, R. E. (2003). Discordant Outcomes following Failure of Antiretroviral Therapy Are Associated with Substantial Differences in Human Immunodeficiency Virus-Specific Cellular Immunity. J. Virol. 77: 6041-6049 [Abstract] [Full text]  
• Aslanzadeh, J. (2002). HIV Resistance Testing: an Update. Annals of Clinical & Laboratory Science 32: 406-413 [Abstract] [Full text]  
• (2002). Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol 31: 951-958 [Abstract] [Full text]  
• Anastos, K., Barron, Y., Miotti, P., Weiser, B., Young, M., Hessol, N., Greenblatt, R. M., Cohen, M., Augenbraun, M., Levine, A., Munoz, A., for the Women's Interagency HIV Study Collaborativ, (2002). Risk of Progression to AIDS and Death in Women Infected With HIV-1 Initiating Highly Active Antiretroviral Treatment at Different Stages of Disease. Arch Intern Med 162: 1973-1980 [Abstract] [Full text]  
• Del Amo, J, Del Romero, J, Barrasa, A, Perez-Hoyos, S, Rodriguez, C, Diez, M, Garcia, S, Soriano, V, Castilla, J, the Grupo de Seroconvertores de la Comunidad de Ma, (2002). Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999. Sex. Transm. Infect. 78: 255-260 [Abstract] [Full text]  
• Goldie, S. J., Kaplan, J. E., Losina, E., Weinstein, M. C., Paltiel, A. D., Seage III, G. R., Craven, D. E., Kimmel, A. D., Zhang, H., Cohen, C. J., Freedberg, K. A. (2002). Prophylaxis for Human Immunodeficiency Virus-Related Pneumocystis carinii Pneumonia: Using Simulation Modeling to Inform Clinical Guidelines. Arch Intern Med 162: 921-928 [Abstract] [Full text]  
• Jacobson, L. P., Li, R., Phair, J., Margolick, J. B., Rinaldo, C. R., Detels, R., Munoz, A. (2002). Evaluation of the Effectiveness of Highly Active Antiretroviral Therapy in Persons with Human Immunodeficiency Virus using Biomarker-based Equivalence of Disease Progression. Am J Epidemiol 155: 760-770 [Abstract] [Full text]  
• Jordan, R., Gold, L., Cummins, C., Hyde, C. (2002). Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ 324: 757-757 [Abstract] [Full text]  
• Gange, S J, Barron, Y, Greenblatt, R M, Anastos, K, Minkoff, H, Young, M, Kovacs, A, Cohen, M, Meyer, W A III, Munoz, A (2002). Effectiveness of highly active antiretroviral therapy among HIV-1 infected women. J. Epidemiol. Community Health 56: 153-159 [Abstract] [Full text]  
• Kirk, O., Pedersen, C., Cozzi-Lepri, A., Antunes, F., Miller, V., Gatell, J. M., Katlama, C., Lazzarin, A., Skinhoj, P., Barton, S. E. (2001). Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 98: 3406-3412 [Abstract] [Full text]  
• Kahn, J. G., Haile, B., Kates, J., Chang, S. (2001). Health and Federal Budgetary Effects of Increasing Access to Antiretroviral Medications for HIV by Expanding Medicaid. AJPH 91: 1464-1473 [Abstract] [Full text]  
• Mittler, J., Essunger, P., Yuen, G. J., Clendeninn, N., Markowitz, M., Perelson, A. S. (2001). Short-Term Measures of Relative Efficacy Predict Longer-Term Reductions in Human Immunodeficiency Virus Type 1 RNA Levels following Nelfinavir Monotherapy. Antimicrob. Agents Chemother. 45: 1438-1443 [Abstract] [Full text]  
• Parpia, T., Raab, G. M., Goldberg, D. J., Allardice, G. M., McMenamin, J., Whitelaw, J., McSharry, C., Potts, R., Herriot, R. (2001). Effect of Combination Therapy on Immunologic Progression of Human Immunodeficiency Virus at a Population Level. Am J Epidemiol 153: 898-902 [Abstract] [Full text]  
• Sabin, C. A., Phillips, A. N. (2001). Treatment comparisons in HIV infection: the benefits and limitations of observational cohort studies. J Antimicrob Chemother 47: 371-375 [Full text]  
• Collier, A. C., Kalish, L. A., Busch, M. P., Gernsheimer, T., Assmann, S. F., Lane, T. A., Asmuth, D. M., Lederman, M. M., Murphy, E. L., Kumar, P., Kelley, M., Flanigan, T. P., McMahon, D. K., Sacks, H. S., Kennedy, M. S., Holland, P. V., for the Viral Activation Transfusion Study Group, (2001). Leukocyte-Reduced Red Blood Cell Transfusions in Patients With Anemia and Human Immunodeficiency Virus Infection: The Viral Activation Transfusion Study: A Randomized Controlled Trial. JAMA 285: 1592-1601 [Abstract] [Full text]  
• Stingele, K., Haas, J., Zimmermann, T., Stingele, R., Hubsch-Muller, C., Freitag, M., Storch-Hagenlocher, B., Hartmann, M., Wildemann, B. (2001). Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy. Neurology 56: 355-361 [Abstract] [Full text]  
• Ledergerber, B., Mocroft, A., Reiss, P., Furrer, H., Kirk, O., Bickel, M., Uberti-Foppa, C., Pradier, C., d'Arminio Monforte, A., Schneider, M. M.E., Lundgren, J. D. (2001). Discontinuation of Secondary Prophylaxis against Pneumocystis carinii Pneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy. NEJM 344: 168-174 [Abstract] [Full text]  
• International Collaboration on HIV and Cancer, (2000). Highly Active Antiretroviral Therapy and Incidence of Cancer in Human Immunodeficiency Virus-Infected Adults. JNCI J Natl Cancer Inst 92: 1823-1830 [Abstract] [Full text]  
• Ahdieh, L., Gange, S. J., Greenblatt, R., Minkoff, H., Anastos, K., Young, M., Nowicki, M., Kovacs, A., Cohen, M., Munoz, A. (2000). Selection by Indication of Potent Antiretroviral Therapy Use in a Large Cohort of Women Infected with Human Immunodeficiency Virus. Am J Epidemiol 152: 923-933 [Abstract] [Full text]  
• Currier, J. S., Williams, P. L., Koletar, S. L., Cohn, S. E., Murphy, R. L., Heald, A. E., Hafner, R., Bassily, E. L., Lederman, H. M., Knirsch, C., Benson, C. A., Valdez, H., Aberg, J. A., McCutchan, J. A. (2000). Discontinuation of Mycobacterium avium Complex Prophylaxis in Patients with Antiretroviral Therapy-Induced Increases in CD4+ Cell Count: A Randomized, Double-Blind, Placebo-Controlled Trial. ANN INTERN MED 133: 493-503 [Abstract] [Full text]  
• de Martino, M., Tovo, P.-A., Balducci, M., Galli, L., Gabiano, C., Rezza, G., Pezzotti, P., for the Italian Register for HIV Infection in Chil, (2000). Reduction in Mortality With Availability of Antiretroviral Therapy for Children With Perinatal HIV-1 Infection. JAMA 284: 190-197 [Abstract] [Full text]  
• Minkoff, H., Santoro, N. (2000). Ethical Considerations in the Treatment of Infertility in Women with Human Immunodeficiency Virus Infection. NEJM 342: 1748-1750 [Full text]  
• Engels, E. A., Frisch, M., Biggar, R. J., Goedert, J. J., Ledergerber, B., Egger, M., Telenti, A. (2000). AIDS-Related Opportunistic Illness and Potent Antiretroviral Therapy. JAMA 283: 2653-2654 [Full text]  
• Erb, P., Battegay, M., Zimmerli, W., Rickenbach, M., Egger, M., for the Swiss HIV Cohort Study, (2000). Effect of Antiretroviral Therapy on Viral Load, CD4 Cell Count, and Progression to Acquired Immunodeficiency Syndrome in a Community Human Immunodeficiency Virus-Infected Cohort. Arch Intern Med 160: 1134-1140 [Abstract] [Full text]  
• Petropoulos, C. J., Parkin, N. T., Limoli, K. L., Lie, Y. S., Wrin, T., Huang, W., Tian, H., Smith, D., Winslow, G. A., Capon, D. J., Whitcomb, J. M. (2000). A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 44: 920-928 [Abstract] [Full text]  
• Imamichi, T., Sinha, T., Imamichi, H., Zhang, Y.-M., Metcalf, J. A., Falloon, J., Lane, H. C. (2000). High-Level Resistance to 3'-Azido-3'-Deoxythimidine due to a Deletion in the Reverse Transcriptase Gene of Human Immunodeficiency Virus Type 1. J. Virol. 74: 1023-1028 [Abstract] [Full text]  
• Ledergerber, B., Egger, M., Erard, V., Weber, R., Hirschel, B., Furrer, H., Battegay, M., Vernazza, P., Bernasconi, E., Opravil, M., Kaufmann, D., Sudre, P., Francioli, P., Telenti, A., for the Swiss HIV Cohort Study, (1999). AIDS-Related Opportunistic Illnesses Occurring After Initiation of Potent Antiretroviral Therapy: The Swiss HIV Cohort Study. JAMA 282: 2220-2226 [Abstract] [Full text]  
• Sendi, P. P., Craig, B. A., Meier, G., Pfluger, D., Gafni, A., Opravil, M., Battegay, M., Bucher, H. C. (1999). Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. J Antimicrob Chemother 44: 811-817 [Abstract] [Full text]  
• Chang, L., Ernst, T., Leonido-Yee, M., Witt, M., Speck, O., Walot, I., Miller, E. N. (1999). Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. Neurology 53: 782-782 [Abstract] [Full text]  
• Periard, D., Telenti, A., Sudre, P., Cheseaux, J.-J., Halfon, P., Reymond, M. J., Marcovina, S. M., Glauser, M. P., Nicod, P., Darioli, R., Mooser, V. (1999). Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors. Circulation 100: 700-705 [Abstract] [Full text]  
• Weber, R., Ledergerber, B., Zbinden, R., Altwegg, M., Pfyffer, G. E., Spycher, M. A., Briner, J., Kaiser, L., Opravil, M., Meyenberger, C., Flepp, M., for the Swiss HIV Cohort Study, (1999). Enteric Infections and Diarrhea in Human Immunodeficiency Virus-Infected Persons: Prospective Community-Based Cohort Study. Arch Intern Med 159: 1473-1480 [Abstract] [Full text]  
• Ledergerber, B., Telenti, A., Egger, M. (1999). Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. BMJ 319: 23-24 [Full text]  
• Furrer, H., Egger, M., Opravil, M., Bernasconi, E., Hirschel, B., Battegay, M., Telenti, A., Vernazza, P. L., Rickenbach, M., Flepp, M., Malinverni, R., The Swiss HIV Cohort Study, (1999). Discontinuation of Primary Prophylaxis against Pneumocystis carinii Pneumonia in HIV-1-Infected Adults Treated with Combination Antiretroviral Therapy. NEJM 340: 1301-1306 [Abstract] [Full text]  
• Detels, R., Munoz, A., McFarlane, G., Kingsley, L. A., Margolick, J. B., Giorgi, J., Schrager, L. K., Phair, J. P., for the Multicenter AIDS Cohort Study Investigator, (1998). Effectiveness of Potent Antiretroviral Therapy on Time to AIDS and Death in Men With Known HIV Infection Duration. JAMA 280: 1497-1503 [Abstract] [Full text]  
• Pialoux, G., Raffi, F., Brun-Vezinet, F., Meiffredy, V., Flandre, P., Gastaut, J.-A., Dellamonica, P., Yeni, P., Delfraissy, J.-F., Aboulker, J.-P., The Trilege (Agence Nationale de Recherches sur le, (1998). A Randomized Trial of Three Maintenance Regimens Given after Three Months of Induction Therapy with Zidovudine, Lamivudine, and Indinavir in Previously Untreated HIV-1-Infected Patients. NEJM 339: 1269-1276 [Abstract] [Full text]  
• Knobel, H., Carmona, A., Grau, S., Pedro-Botet, J., Diez, A. (1998). Adherence and Effectiveness of Highly Active Antiretroviral Therapy. Arch Intern Med 158: 1953-1953 [Full text]  
• McMenamin, J., Allardice, G., Goldberg, D., Parpira, T., Raab, G., Thiébaut, R., Thiessard, F., Merchadou, L. D., Marimoutou, C., Dabis, F. (1998). Antiretroviral combination therapy and HIV infection. BMJ 317: 887-887 [Full text]  
• Perrin, L., Telenti, A. (1998). HIV Treatment Failure: Testing for HIV Resistance in Clinical Practice. Science 280: 1871-1873 [Abstract] [Full text]  
• Hirschel, B., Francioli, P. (1998). Progress and Problems in the Fight against AIDS. NEJM 338: 906-908 [Full text]  
• Mocroft, A., Youle, M., Phillips, A. N., Halai, R., Easterbrook, P., Johnson, M. A., Gazzard, B., for the Royal Free/Chelsea and Westminster Hospita, (1998). The Incidence of AIDS-Defining Illnesses in 4883 Patients With Human Immunodeficiency Virus Infection. Arch Intern Med 158: 491-497 [Abstract] [Full text]  
• Hogg, R. S., Heath, K. V., Yip, B., Craib, K. J. P., O'Shaughnessy, M. V., Schechter, M. T., Montaner, J. S. G. (1998). Improved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral Therapy. JAMA 279: 450-454 [Abstract] [Full text]  
• (1997). HIV AND THE NEW ANTIRETROVIRALS: IMPACT IN THE COMMUNITY. JWatch General 1997: 3-3 [Full text]